In conclusion, we report that clinical risk scores to predict microvascular events in patients with type 2 diabetes can be developed using classical CVD and diabetes-related risk factors. We further show that NT-proBNP and hsTnT can add moderate information to these clinical risk scores for nephropathy events. Further work is required to establish whether the prediction of microvascular risk can be improved using a variety of biomarkers.